view map
  • Finland
  • Norway
  • Sweden
  • Estonia
  • Russian Federation
  • Latvia
  • Denmark
  • Lithuania
  • United Kingdom
  • Netherlands
  • Ireland
  • Poland
  • Germany
  • Belgium
  • Czech Republic
  • Ukraine
  • Slovakia
  • Luxembourg
  • Moldova, Republic of
  • Austria
  • France
  • Switzerland
  • Romania
  • Slovenia
  • Croatia
  • Serbia
  • Bosnia & Herzegovina
  • Bulgaria
  • Italy
  • Macedonia, the Former Yugoslav Republic of
  • Spain
  • Greece
  • Israel

AAV Gene Therapy For Neuronopathic Gaucher Disease and Parkinson's Disease with a GBA Mutation

5 August 2020

Taking place on Monday 5th Ocober from 3-4:30pm (BST), this is the second in a series of educational webinars for our members on the latest developments in gene therapy will focus on AAV-based gene therapy and Prevail Therapeutic's approach for neuronopathic Gaucher disease and Parkinson's disease with a GBA mutation.

Dr Heather Lau from the NYU School of Medicine will moderate the call and our speakers will be Eriene Wasef (Medical Director) and Olga Uspenskaya-Cadoz (Vice President, Clinical Development) from Prevail. 

Click here to register

Click here for more details about Prevail's gene therapy.


Eriene is a pharmacist with over 16 years of diverse clinical research experience, predominantly within neurological and psychiatric disorders, including pediatric rare diseases. She joined Prevail Therapeutics in 2019 as the Medical Director for the neuronopathic Gaucher disease clinical research program. Prior to joining Prevail, she served as a Sr. Principle Scientist at Hoffmann-La Roche, where she had clinical and scientific responsibilities for multiple research programs from preclinical through Phase 2.   Prior to her time at Roche, Eriene worked within Clinical Development at Janssen LP, a division of J&J. She has worked in a variety of healthcare settings, including as a Consultant Pharmacist for the State of NJ, primarily in Greystone Park Psychiatric Hospital. Eriene received her BS and Doctor of Pharmacy from the Ernest B Mario School of Pharmacy at Rutgers University.

Olga is a neurologist and serves at Prevail Therapeutics as Vice President, Clinical Development. She earned her MD and completed a residency in neurology at the First Moscow State Medical University. Subsequently, Olga completed a PhD program in neurosciences at First Moscow State Medical University and Ludwig-Maximilians University, Munich, Germany; and a post-doctoral fellowship at the Sorbonne University Hospital Pitié-Salpêtrière, Paris, France. During her clinical and research career Olga held academic positions which included research grants and lecturing on neurology topics. Olga has published in peer-reviewed clinical related journals, contributed to the chapters in neurology textbooks, as well as presented at neurology conferences worldwide. 

Prior to joining Prevail, Olga served as senior medical director at IQVIA where she was responsible for the medical strategy of the neurology portfolio and was overseeing execution of CNS clinical trials across different stages of clinical development. 

Heather Lau, M.D. M.S. is a board certified neurologist with special qualifications in child neurology. Dr. Lau received her bachelor of science with honors from Cornell University and a master of science in biochemistry and molecular biology from New York Medical College. She went on to receive her doctorate of medicine from the University of Rochester.  She trained in pediatrics at Montefiore Medical Center and completed her child neurology training as well as additional fellowship training in Neurogenetics from New York University.

Dr. Lau is currently assistant professor in Child Neurology at NYU School of Medicine and the Director of the NYU Lysosomal Storage Disorders Program at NYU Langone Health. She maintains a large and diverse practice of patients with rare, inherited disorders of the nervous system with a special interest in lysosomal storage disorders and leukodystrophies. Dr. Lau is actively engaged in clinical research and has been a principal investigator for over 20 interventional trials and disease registries evaluating enzyme replacement therapies, small molecules, and gene therapy.  She has 19 original peer-reviewed publications and over 30 published abstracts in this field of medicine and has presented at various congresses and international meetings. 

Dr Lau is an advisory board member for National Tay Sachs and Allied Diseases, SHIRE Gaucher Outcome Survey, and Adult Polyglucosan Body Foundation. She has taught several courses on neurogenetics and neurologic manifestations of mucopolysaccharidoses at NYU Division of Child Neurology.